banner
onclive.bsky.social
OncLive
@onclive.bsky.social
910 followers 140 following 2.2K posts
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Posts Media Videos Starter Packs
onclive.bsky.social
OncLive @onclive.bsky.social · 11h
Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology #urothelialcancer #urology
www.onclive.com/view/urothel...
onclive.bsky.social
OncLive @onclive.bsky.social · 12h
BREAKING 🚨: @fda.gov Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma #cscc #oncology

Read more: onclive.com/view/fda-app...
onclive.bsky.social
OncLive @onclive.bsky.social · 14h
FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma
#oncology #lcsm #mesothelioma
www.onclive.com/view/fda-gra...
FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma | OncLive
VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 15h
WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy @fda.gov #melsm #oncology
www.onclive.com/view/wtx-124...
WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy | OncLive
WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 18h
FDA Issues CRL for Dasatinib in Chronic Myeloid #Leukemia #oncology

www.onclive.com/view/fda-app...
FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia | OncLive
The FDA has approved dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 18h
Targeted Therapies Move the Needle in #NSCLC #oncology

www.onclive.com/view/taarget...
Targeted Therapies Move the Needle in NSCLC | OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 1d
CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer
#OvarianCancer #gyncsm
www.onclive.com/view/cdk4-6-...
CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer | OncLive
CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 1d
NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ #NSCLC #oncology

www.onclive.com/view/nice-re...
NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ NSCLC | OncLive
Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 1d
Dana-Farber Proposes Proton Therapy Center, Offering Leading Edge Treatment to Patients
@danafarber.bsky.social #Oncology
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 1d
sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer #BreastCancer #bcsm #oncology
www.onclive.com/view/snda-su...
sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer | OncLive
A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 1d
HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell #Lymphoma #oncology

www.onclive.com/view/hybryte...
HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell Lymphoma | OncLive
A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 1d
AI Integration and Systemic Reform Are Needed to Balance Resource Protection With Timely Access to Treatment
#oncology #AI
www.onclive.com/view/ai-inte...
AI Integration and Systemic Reform Are Needed to Balance Resource Protection With Timely Access to Treatment | OncLive
Emerging technologies and process reconsiderations may alleviate time and resource stressors oncology teams face when appealing patient insurance denials.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 1d
The FDA Approval of Intravesical Mitomycin in #NMIBC Follows #ODAC Debate on Need for Randomized Data

Read more here ⬇️
www.onclive.com/view/fda-app...
FDA Approval of Intravesical Mitomycin in NMIBC Follows ODAC Debate on Need for Randomized Data | OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 2d
Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL #leusm #hematology
www.onclive.com/view/retrosp...
Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL | OncLive
BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 2d
New Study Links Genetic Variation to Chemotherapy-Related Liver Damage in Patients With Colorectal Cancer Liver Metastases @mayocliniccancer.bsky.social @mayoclinic.org #crcsm #oncology
www.onclive.com/view/new-stu...
New Study Links Genetic Variation to Chemotherapy-Related Liver Damage in Patients With Colorectal Cancer Liver Metastases | OncLive
A genetic factor may explain why some patients with colorectal cancer that has spread to the liver experience liver damage after chemotherapy.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 2d
First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC #oncology #bcsm #TNBC
www.onclive.com/view/first-l...
First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC | OncLive
Dato-DXd displayed topline survival benefits in patients with recurrent/metastatic TNBC who could not receive immunotherapy.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 2d
FDA Grants Priority Review to Orca-T for Hematologic Malignancies @fda.gov #oncology #hematology
www.onclive.com/view/fda-gra...
FDA Grants Priority Review to Orca-T for Hematologic Malignancies | OncLive
The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 2d
Bevacizumab Plus Erlotinib Shows Antitumor Activity in Advanced Papillary Renal Cell Carcinoma #oncology

www.onclive.com/view/bevaciz...
Bevacizumab Plus Erlotinib Shows Antitumor Activity in Advanced Papillary Renal Cell Carcinoma | OncLive
Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 3d
Older Cancer Clinical Trials May Continue to Offer Relevant Lessons Learned
#ClinicalTrials #Oncology
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 4d
Case Study Showcases Potential Role of Targeted Therapy for Secondary T-Cell Lymphoma After CAR T-Cell Therapy
#lymsm #secondarymalignancy
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 5d
As Q4 begins, the oncology community is closely watching the @fda.gov for several key regulatory decisions.

Sign up 🔐 to access the full list of decisions to watch and what they could mean for clinical practice: www.onclive.com/view/q4-2025...
onclive.bsky.social
OncLive @onclive.bsky.social · 5d
OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025
@myesmo.bsky.social #BreastCancer #bcsm
www.onclive.com/view/onclive...
OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025 | OncLive
Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.
www.onclive.com
2
onclive.bsky.social
OncLive @onclive.bsky.social · 5d
It's here! Your guide to all the oncologic therapeutic options that were greenlit ✅ by the @fda.gov in September 2025.

Check out the full resource: www.onclive.com/view/onclive...
onclive.bsky.social
OncLive @onclive.bsky.social · 5d
Case Study Highlights Tumor Burden Reduction With Paxalisib Combo in Metastatic TNBC
#TNBC #BreastCancer #BCSM
www.onclive.com/view/case-st...
Case Study Highlights Tumor Burden Reduction With Paxalisib Combo in Metastatic TNBC | OncLive
Paxalisib plus pembrolizumab and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer.
www.onclive.com
onclive.bsky.social
OncLive @onclive.bsky.social · 5d
Real-World Study Demonstrates Safety and Efficacy of Avelumab/Axitinib in Advanced #RCC #oncology

www.onclive.com/view/real-wo...
Real-World Study Demonstrates Safety and Efficacy of Avelumab/Axitinib in Advanced RCC | OncLive
A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.
www.onclive.com